Chinese Pharma Licensing Deals Hit Record in H1
The innovative Chinese pharmaceutical industry achieved a new record in the first half of 2026, with the value of its external licensing deals exceeding $100 billion. Approvals included the marketing of 38 innovative drugs, of which 31 were developed by local companies, accompanied by a 6.4% growth in the value-added industrial output compared to the previous year. Additionally, industry exports increased to approximately $30.91 billion, with a rising share of high-value-added products, such as biologics and ready-to-use chemical doses, in total exports.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)